DeepMed Research

JEIL PHARMACEUTICAL CO., LTD.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Employees: 999

Market Cap: -

Website: http://www.jeilpharm.co.kr

Clinical Trials

Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

Phase 3

Completed

Conditions: Dyslipidemia With Hypertension

Interventions: Drug: Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)
Drug: Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)
Drug: Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)

First Posted Date: 2017-03-23

Last Posted Date: 2018-07-06

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 126

Registration Number: NCT03088254

Locations: 🇰🇷
Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

and more 9 locations

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Phase 2

Conditions: Acute Ischemic Stroke

Interventions: Drug: JPI-289 Low-dose
Drug: JPI-289 High-dose
Drug: Placebo

First Posted Date: 2017-02-23

Last Posted Date: 2019-11-18

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 110

Registration Number: NCT03062397

Locations: 🇰🇷
Jeju National University Hospital, Jeju, Korea, Republic of
🇰🇷
Ewha Womans University Seoul Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

and more 12 locations

The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes
Hyperlipidemia

Interventions: Drug: Metformin + Rosuvastatin
Drug: JLP-1310

First Posted Date: 2016-12-05

Last Posted Date: 2018-03-29

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT02982798

Locations: 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH

Phase 3

Completed

Conditions: Lower Urinary Tract Symptoms
Benign Prostatic Hyperplasia

Interventions: Drug: Tamsulosin 0.2mg + Solifenacin 5mg
Drug: Tamsulosin 0.2mg + Placebo(Solifenacin)

First Posted Date: 2016-11-23

Last Posted Date: 2019-08-29

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 780

Registration Number: NCT02972268

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

Phase 3

Completed

Conditions: Type 2 Diabetes
Dyslipidemia

Interventions: Drug: placebo + Rosuvastatin
Drug: Metformin + Rosuvastatin
Drug: Metformin + placebo

First Posted Date: 2016-07-11

Last Posted Date: 2018-07-06

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 237

Registration Number: NCT02827903

Locations: 🇰🇷
Youngnam University Hostpital, Daegu, Korea, Republic of
🇰🇷
Myoung Ji Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Daeheon Eulji Medical Center, Daejeon, Korea, Republic of

and more 30 locations

The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.

Phase 1

Completed

Conditions: Overactive Bladder
Benign Prostatic Hyperplasia
LUTS(Lower Urinary Tract Symptoms)

Interventions: Drug: Solifenacin 5mg+Tamsulosin 0.2mg
Drug: JLP-1207

First Posted Date: 2015-07-10

Last Posted Date: 2016-06-24

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 54

Registration Number: NCT02494349

Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes
Hyperlipidemia

Interventions: Drug: JLP-1310, Fasted followed by fed
Drug: JLP-1310, Fed followed by fasted

First Posted Date: 2015-05-20

Last Posted Date: 2018-03-29

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT02449187

Locations: 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Overactive Bladder
LUTS
Benign Prostatic Hyperplasia

Interventions: Drug: JLP-1207(Fasted)
Drug: JLP-1207(Fed)

First Posted Date: 2015-05-18

Last Posted Date: 2016-06-24

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 54

Registration Number: NCT02447367

Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent

Phase 4

Completed

Conditions: ANEURYSM CORONARY ARTERY

Interventions: Drug: Clopirin 1
Drug: Clopidogrel-Aspirin(co-administration) 1
Drug: Clopirin 2
Drug: Clopidogrel-Aspirin(co-administration) 2

First Posted Date: 2015-04-07

Last Posted Date: 2017-03-14

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 448

Registration Number: NCT02410083

The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Stroke

Interventions: Drug: Placebo
Drug: JPI-289

First Posted Date: 2015-03-24

Last Posted Date: 2016-06-24

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT02396069

Locations: 🇰🇷
Asan Medical Center, Seoul, Songpa-Gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy